Brief: Acura Pharmaceuticals initiates clinical study of meth-resistant Nexafed extended-release formulations
16/02/2015 11:30
Feb 16 (Reuters) - Acura Pharmaceuticals Inc ACUR.O : * Initiates clinical study of meth-resistant Nexafed(R) extended-release formulations * Source text for Eikon ID:nMKWDRwtha * Further company coverage ACUR.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Acura Pharmaceuticals
See all newsBrief: Acura Pharmaceuticals Received A $250,000 Loan From Abuse Deterrent Pharma, LLC on October 11
Brief: Acura Pharmaceuticals Inc Receives $200,000 Loan From Abuse Deterrent Pharma
Brief: Acura Pharmaceuticals Received $250,000 Loan From AD Pharma For Operations Through End Of April 2023
Brief: Acura Pharmaceuticals, AD Pharma Amend License to LIMITx LTX-03
Insight: Novavax bosses cash out for $46 mln with COVID-19 vaccine trials still under way